Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 20, 2026 09:00 ET | Source: Oncolytics Biotech, Inc.

Oncolytics Biotech® Receives Fast Track Designation for Pelareorep in Second-Line and Later Anal Cancer

Oncolytics announced the FDA has granted Fast Track designation to pelareorep in combination with a checkpoint inhibitor for squamous cell anal cancer.
July 16, 2026 10:44 ET | Source: Trethera Corporation

Trethera and UCLA Publish Comprehensive Review Highlighting Deoxycytidine Kinase as a Novel Metabolic Target for Cancer Therapy

Trethera and UCLA publish peer-reviewed manuscript highlighting dCK as a novel cancer target and TRE-515 as the first clinically tested dCK inhibitor
July 07, 2026 09:42 ET | Source: BCC Research LLC

Chronic Kidney Disease Market to Reach $131.4 Billion by 2030, Driven by Rising Prevalence and Healthcare Infrastructure Investment

Examines the evolving competitive landscape, regulatory developments & investment trends shaping the future of chronic kidney disease management worldwide.
July 07, 2026 07:00 ET | Source: Teva Pharmaceutical Industries Ltd

Teva to Advance Its Anti-IL-15 Antibody, Designed for Quarterly Dosing, Into Phase 2b Development in Vitiligo, Following Encouraging Phase 1b Results

Teva-discovered TEV-’408 targets IL-15, a key driver of vitiligo biology TEV-’408 showed improvement in skin pigmentation and was well-tolerated with no safety signals observed to dateNearly 75% of...
July 07, 2026 07:00 ET | Source: Kymera Therapeutics, Inc.

Kymera Therapeutics Appoints Elizabeth Laws, Ph.D., as Senior Vice President, Global Program Team Leader for KT-621, First-in-Class, Oral STAT6 Degrader

Dr. Laws, former immunology leader at Sanofi, will oversee global development of Kymera’s KT-621 program KT-621 parallel Phase 2b trials advancing in AD and asthma, with data expected by year-end...
July 06, 2026 07:35 ET | Source: Research and Markets

Fair-Market Value Rates Revealed in New US Rheumatology Thought Leader Compensation Report

Dublin, July 06, 2026 (GLOBE NEWSWIRE) -- The "Fair-Market Value Compensation Rates for Rheumatology KOLs - United States" has been added to ResearchAndMarkets.com's offering. The Thought...
July 02, 2026 07:00 ET | Source: VERAXA Biotech GmbH

VERAXA Biotech Initiates Cell Line Development with ATUM to Advance its Lead BiTAC®-TCE Program

VERAXA Biotech announces further progress with lead BiTAC® T-cell engager (BiTAC-TCE) program, initiates cell line development with ATUM.
July 02, 2026 04:00 ET | Source: Anaveon

Anaveon Appoints Laetitia Pouzol as Chief Scientific Officer

Anaveon appoints Laetitia Pouzol as Chief Scientific Officer.
June 26, 2026 12:45 ET | Source: Johnson & Johnson EMEA

Johnson & Johnson presents new IMAAVY®▼ (nipocalimab) data at European Academy of Neurology (EAN) 2026 Congress reinforcing sustained disease control in generalised myasthenia gravis

New analyses from the Phase 3 Vivacity-MG3 study support the impact of nipocalimab in anti-AChR+a, anti-MuSK+b adult patients with generalised myasthenia gravis (gMG) including those early in their...
June 25, 2026 07:00 ET | Source: Kymera Therapeutics, Inc.

Kymera Therapeutics Completes Enrollment in the Phase 2b BROADEN2 Trial of KT-621 in Atopic Dermatitis with Topline Data by Year-end 2026

BROADEN2 enrollment completed nearly six months ahead of anticipated timelines KT-621 Phase 3 trials in AD planned to initiate by mid-2027 KT-621 BREADTH Phase 2b asthma trial ongoing, with data...